| Type size: |
 |
 |
|
|
Press Releases
Sign up to receive email notifications of new Press Release.
|
|
 = Add Release to Briefcase |
| All Releases |
|---|
 |
Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
Jul 01, 2008
|
7.7 KB
|
| |
SOUTH SAN FRANCISCO, Calif., July 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that William D. Young, CEO and Chairman, is scheduled to present an update on the company's business at the Collins Stewart LLC Fourth Annual Growth Conference on Tuesday, July 8, 2008 at 9:00 a.m. (E...
|
|
|
Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
Jun 18, 2008
|
11.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced today that the Company has signed an agreement with Gilead Sciences, Inc. to provide resistance testing and consultative services for Gilead's Elvitegravir Phase III studies. Monogram assays will be used ...
|
|
|
Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
Jun 16, 2008
|
12.8 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that data related to the enhanced performance of the company's HIV tropism assay were presented in an oral presentation at the 17th International HIV Drug Resistance Workshop in Sitges, Spain. Trofil...
|
|
|
Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
Jun 05, 2008
|
12.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced immediate availability of enhanced sensitivity in its Trofile assay. Trofile was introduced commercially upon FDA approval of Selzentry(TM) (maraviroc), Pfizer's first in class CCR5 antagonist, in Aug...
|
|
|
Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
Jun 02, 2008
|
13.8 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 2, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that scientific collaborators have presented additional clinical results on HERmark(TM), the company's novel oncology assay, as a means to measure HER2 total protein and homodimer levels and predict r...
|
|
|
Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
May 16, 2008
|
12.2 KB
|
| |
SOUTH SAN FRANCISCO, Calif., May 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that scientific collaborators will present results on HERmark(TM), the company's novel oncology assay, as a means to measure HER2 and predict response to Herceptin(R) (trastuzumab) in patients with me...
|
|
|
HER1 and HER3 VeraTag™ Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
May 01, 2008
|
11.1 KB
|
| |
SOUTH SAN FRANCISCO, May 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that the company's HER1 and HER3 Quantitative Protein Assays are now available for clinical development use. Built on Monogram's VeraTag™ platform, the HER1 and HER3 assa...
|
|
|
Monogram Announces 2008 First Quarter Financial Results
May 01, 2008
|
22.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., May 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today reported financial results for the quarter ended March 31, 2008.
The Company had revenue of $14.8 million for the first quarter of 2008, 57% higher than $9.4 million in the first quarter of 2007. This growth...
|
|
|
Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
Apr 21, 2008
|
7.6 KB
|
| |
SOUTH SAN FRANCISCO, Calif., April 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference call on Thursday, May 1, 2008 at 4:30 p.m. (Eastern Time) to discuss first quarter 2008 financial results. The call will be hosted by Mr. William D. Young, Chairman and CEO...
|
|
|
Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
Apr 14, 2008
|
7.8 KB
|
| |
SOUTH SAN FRANCISCO, Calif., April 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that William D. Young, CEO and Chairman, is scheduled to present a corporate overview at the Seventh Annual JMP Securities Research Conference on Wednesday, May 21, 2008 at 5:00 p.m. Eastern Time (2...
|
|
|
New York Medicaid Program Establishes Coverage for Trofile(TM)
Apr 08, 2008
|
11.4 KB
|
| |
SOUTH SAN FRANCISCO, Calif., April 8, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that New York Medicaid has established coverage and reimbursement for Monogram's Trofile Assay, a diagnostic used to determine patient candidacy for Pfizer's new HIV anti-viral medication Selze...
|
|
|
Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
Apr 01, 2008
|
11.6 KB
|
| |
SOUTH SAN FRANCISCO, Calif., April 1, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced today that it had entered into an agreement with Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) to provide resistance and tropism testing for Progenics' clinical development program of PRO 140, an i...
|
|
|
Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
Mar 31, 2008
|
12.3 KB
|
| |
SOUTH SAN FRANCISCO, Calif., March 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that company researchers have co-authored with collaborators from Maxygen, Inc. and Aldevron LLC several important abstracts presented during the Keystone HIV Vaccines: Progress and Prospects Sympos...
|
|
|
Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
Mar 25, 2008
|
10.8 KB
|
| |
SOUTH SAN FRANCISCO, Calif., March 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced the promotion of Gordon Parry, PhD, to the position of Vice President, Research and Development, Oncology. Dr. Parry will have responsibility for Monogram's oncology research and development program...
|
|
|
California Medicaid Establishes Coverage for Trofile(TM)
Mar 17, 2008
|
11.3 KB
|
| |
SOUTH SAN FRANCISCO, Calif., March 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that the California Medicaid program (Medi-Cal) has established coverage and reimbursement for Monogram's Trofile Assay.
Medi-Cal is the state medical assistance program in California establishe...
|
|
|
Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
Mar 10, 2008
|
11.7 KB
|
| |
SOUTH SAN FRANCISCO, Calif., March 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced today that the Company has signed an agreement with AVEXA Limited (ASX: AVX) to be the exclusive provider of HIV resistance and tropism testing technology in support of Avexa's drug discovery and develop...
|
|
|
Monogram Announces 2007 Year-End Financial Results
Feb 07, 2008
|
23.5 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today reported financial results for the quarter and year ended December 31, 2007.
The Company had revenue of $13.7 million for the fourth quarter of 2007, 34% higher than $10.2 million in the fourth quarter of 2...
|
|
|
Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
Feb 07, 2008
|
13.7 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc (Nasdaq: MGRM) today announced that data related to the company's advanced HIV tropism assay have been presented as multiple posters during the 15th Conference on Retroviruses and Opportunistic Infections (CROI) this week in Boston,...
|
|
|
DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use
Feb 04, 2008
|
11.9 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Feb 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) today announced that guidelines issued by the Department of Health and Human Services (DHHS) recommend that a co-receptor tropism test, such as Monogram's Trofile(TM) assay, should be performed whenever the use of a ...
|
|
|
Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
Jan 30, 2008
|
8.2 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Jan 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference call on Thursday, February 7, 2008 at 4:30 p.m. (Eastern Time) to discuss fourth quarter 2007 financial results and to discuss the outlook for 2008. The call will be hosted b...
|
|
|
|
 |
| Click here to get Corporate Fact Sheet, Backgrounders, Annual Reports.
|
|
 |
|
 |
Click here to view recent HIV scientific publications.
Click here to view recent oncology scientific publications.
|
|
 |
|
|
